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Sotos syndrome is a childhood overgrowth syndrome characterized by a distinctive facial appearance, height and
head circumference 197th percentile, advanced bone age, and developmental delay.Weaver syndrome is characterized
by the same criteria but has its own distinctive facial gestalt. Recently, a 2.2-Mb chromosome 5q35 microdeletion,
encompassingNSD1,was reported as the major cause of Sotos syndrome, with intragenicNSD1mutations identified
in a minority of cases. We evaluated 75 patients with childhood overgrowth, for intragenic mutations and large
deletions of NSD1. The series was phenotypically scored into four groups, prior to the molecular analyses: the
phenotype in group 1 ( ) was typical of Sotos syndrome; the phenotype in group 2 ( ) was Sotos-likenp 37 np 13
but with some atypical features; patients in group 3 ( ) had Weaver syndrome, and patients in group 4np 7
( ) had an overgrowth condition that was neither Sotos nor Weaver syndrome. We detected three deletionsnp 18
and 32 mutations (13 frameshift, 8 nonsense, 2 splice-site, and 9 missense) that are likely to impairNSD1 functions.
The truncating mutations were spread throughoutNSD1, but there was evidence of clustering of missensemutations
in highly conserved functional domains between exons 13 and 23. There was a strong correlation between presence
of an NSD1 alteration and clinical phenotype, in that 28 of 37 (76%) patients in group 1 had NSD1 mutations
or deletions, whereas none of the patients in group 4 had abnormalities of NSD1. Three patients with Weaver
syndrome had NSD1 mutations, all between amino acids 2142 and 2184. We conclude that intragenic mutations
of NSD1 are the major cause of Sotos syndrome and account for some Weaver syndrome cases but rarely occur
in other childhood overgrowth phenotypes.
Introduction
Sotos syndrome (MIM 117550), previously known as
“cerebral gigantism,” was initially described in 1964,
with hundreds of cases subsequently reported (Sotos et
al. 1964; Cole and Hughes 1994). The cardinal features
are pre- and postnatal accelerated somatic growth, char-
acteristic facial appearance (i.e., macrocephaly, promi-
nent jaw, and a high hairline with sparse hair growth),
advanced bone age, and developmental delay (Cole and
Hughes 1994). Additional features that may be present
include neonatal hypotonia, seizures, scoliosis, strabis-
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mus, congenital heart defects, and cancer (Kaneko et al.
1987; Hersh et al. 1992; Cole and Hughes 1994; Noreau
et al. 1998; Opitz et al. 1998; Sweeney et al. 2002). To
date, the diagnosis of Sotos syndrome has been based
primarily on the presence of the characteristic facial ap-
pearance in a large child (fig. 1A). However, although
the combination of craniofacial features is distinctive,
individual components are nonspecific, and diagnosis
can be very difficult for the inexperienced clinician.
Furthermore, phenotypic overlap with other childhood
overgrowth conditions increases the challenge of accu-
rate clinical diagnosis (Cole and Hughes 1994; Cole
1998).
The condition showing greatest phenotypic over-
lap with Sotos syndrome is Weaver syndrome (MIM
277590). This condition was originally described in
1974, and the cardinal features are accelerated growth,
distinctive facies, advanced bone age, and develop-
mental delay (Weaver et al. 1974; Cole et al. 1992).
The facial appearance is somewhat similar to that in
Sotos syndrome, but experienced dysmorphologists be-
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Figure 1 Typical facial phenotype in overgrowth groups 1, 2, and 3. A, Group 1 (classic facial gestalt of Sotos syndrome). B, Group 2
(patients with similarities to Sotos syndrome but with some atypical characteristics; primarily the facial features were not classical). C, Group
3 (Weaver syndrome). Patients in Group 4 did not have a distinctive facial phenotype but were characterized by not having the facial phenotypes
present in the other three groups.
lieve they are distinct (fig. 1C). Additional features
occurring in Weaver syndrome include a hoarse low-
pitched cry, metaphyseal flaring of the femurs, deep-
set nails, prominent finger pads, and camptodactyly
(Cole et al. 1992; Opitz et al. 1998; Proud et al. 1998).
There has been considerable debate as to whether So-
tos and Weaver syndromes are representative of locus
or allelic heterogeneity (Cole 1998; Opitz et al. 1998).
Both Sotos and Weaver syndromes usually occur spo-
radically, although occasional families exhibiting auto-
somal dominant inheritance of these conditions have
been reported (reviewed by Cole and Hughes 1990; Opitz
et al. 1998; Proud et al. 1998). The absence of multiple-
case families has hampered efforts to identify causative
gene(s). However, recently a child with Sotos syndrome
and a t(5;8)(q35;q24.1) translocation was reported (Ima-
izumi et al. 2002), and the gene disrupted by the 5q35
breakpoint was identified as NSD1 (nuclear receptor
SET-domain–containing protein) (Kurotaki et al. 2002).
The functions of NSD1 have not been fully eluci-
dated, but it is thought to act as a transcriptional in-
termediary factor capable of both negatively and pos-
itively influencing transcription, depending on the
cellular context (Huang et al. 1998; Kurotaki et al.
2001). NSD1 contains multiple functional domains, in-
cluding the SET (SU[VAR]3-9,E[Z],trithorax) domain,
which was initially identified in Drosophila genes in-
volved in chromatin-mediated regulation during devel-
opment (reviewed by Jenuwein 2001). NSD1 also con-
tains a SET-associated Cys-rich (SAC) domain adjacent
to the SET domain. The combination of SAC and SET
domains is present in proteins that function as histone-
methyltransferases (HMTases), and both are required
for HMTase activity (Rea et al. 2000). Thus, it is pos-
sible that NSD1 is involved in histone modification and
the regulation and maintenance of chromatin states.
NSD1 also contains five plant homeodomain (PHD)
domains. The PHD domain is a zinc finger–like motif
that predominantly occurs in proteins that function at
the chromatin level (Aasland et al. 1995). The consensus
motif is C4HC3, and NSD1 PHD-I and PHD-IV con-
form to this. However, NSD1 PHD domains II, III, and
V contain a His in place of the final Cys and are thus
known as “PHD-H2 fingers” (Huang et al. 1998).
NSD1 contains two PWWP (proline-tryptophan-tryp-
tophan-proline) domains. The role of the PWWP motif
has not been established, but it is found in regulatory
factors and de novo methyltransferases and is thought
to be involved in protein-protein interactions (Stec et
al. 2000). Finally, NSD1 contains two distinct nuclear
receptor (NR) interaction domains, NIDL and NIDL,
which are found in NR corepressors and coactivators,
respectively (Kurotaki et al. 2001).
Analysis of NSD1 in 42 Japanese patients with spo-
radic Sotos syndrome revealed 19 with a 2.2-Mb micro-
deletion of 5q35 encompassing NSD1 and 4 with intra-
genic NSD1 mutations, predicted to inactivate the
protein (Kurotaki et al. 2002). We have evaluated a phe-
notypically characterized series of patients with over-
growth syndrome for deletions and mutations of NSD1,
to investigate the phenotypic and molecular spectra of
NSD1 aberrations in childhood overgrowth.
Subjects and Methods
Patients
The research was approved by the London Multicentre
Research Ethics Committee, and consent was obtained
from all patients and/or parents. DNA was extracted by
134 Am. J. Hum. Genet. 72:132–143, 2003
standard methods. Samples were obtained from two
sources: 48 patients were ascertained as part of a previous
study and were phenotypically scored independently by
three clinical geneticists (Cole and Hughes 1994). Exten-
sive clinical details and serial photographs of these cases
have been published elsewhere (Cole and Hughes 1990,
1991, 1994, 1995; Cole et al. 1992, 1995). Twenty-seven
patients were ascertained as part of the ongoing Child-
hood Overgrowth Study. Patients eligible for this study
must fulfill four of the following criteria: (a) height 197th
percentile, (b) occipito-frontal circumference 197th per-
centile, (c) bone age 190th percentile, (d) dysmorphic fa-
cial features, (e) developmental delay, and (f) congenital
anomaly or malformations. The 27 newly ascertained pa-
tients were phenotypically scored by three clinical genet-
icists (T.R.P.C., H.E.H., and I.K.T.). All patients were as-
signed to one of four groups: patients in group 1 had
classical Sotos syndrome (fig. 1A); patients in group 2 had
a disease with similarities to Sotos syndrome but with
some atypical characteristics, primarily concerning the fa-
cial features, which were not fully consistent with the
gestalt of Sotos syndrome (fig. 1B); patients in group 3
had Weaver syndrome (fig. 1C); and patients in group 4
had an overgrowth phenotype but did not have either
Sotos syndrome or Weaver syndrome. Within group 4,
there was one patient considered to have Marshall-Smith
syndrome (MIM 602535) and four with a diagnosis of
autosomal dominant macrocephaly (MIM 153470; MIM
605309). The remaining group 4 patients did not have a
specific recognized overgrowth syndrome. Patients with
a confirmed molecular diagnosis of an overgrowth con-
dition, such as Beckwith-Wiedemann syndrome (MIM
130650) or Simpson-Golabi Behmel syndrome (MIM
312870), were excluded. In cases where all three scores
were not concordant, the majority score was accepted.
No patient was scored into three different categories, and
no patient was scored into both groups 1 and 4 or groups
3 and 4 by the assessors. There were high levels of con-
cordant scoring for patients in groups 1, 3, and 4. For
group 2, the level of concordant scoring was lower, with
several patients scored as either group 1 or 4 by one
assessor. Parental DNA was obtained wherever possible.
The numbers of patients and parental samples analyzed
in each group are shown in table 1.
NSD1 Microdeletion Analyses
To identify microdeletions encompassing NSD1, we
analyzed polymorphic microsatellite markers within and
surrounding NSD1. We developed new microsatellite
markers through use of the UCSC Human Genome Pro-
ject Working Draft sequence (UCSC Genome Bioinfor-
matics Web site). We searched the 2-Mb interval en-
compassing NSD1 for dinucleotide, trinucleotide, and
tetranucleotide repeat elements. Flanking amplifying
primers were designed using Primer3 software (Primer3
Web site). All markers were amplified using a touchdown
protocol, cycling from 68C to 50C, with the exception
of SOT19 and SOT20, for which the PCR was per-
formed at a single annealing temperature of 55C. Of
the 22 markers designed, 9 were highly informative and
worked reliably in the analyses. The forward primer for
each marker was end-labeled with g[32P]-ATP, and the
PCR products were electrophoresed on denaturing poly-
acrylamide gels and were exposed to x-ray film. The
positions of the markers relative to NSD1 were calcu-
lated using the UCSC Working Draft sequence. Two
markers, SOT3 and SOT17, are intragenic within intron
2 and intron 17 of NSD1, respectively. All the markers
are well within the 2.2-Mb interval reported as com-
monly deleted in patients with Sotos syndrome (Kuro-
taki et al. 2002). All patients ( ) and parentsnp 75
( ) were analyzed at all markers. The physical lo-np 87
cations relative to NSD1, primer sequences, and sizes of
the nine markers are given in table 2.
Patients who were homozygous at both intragenic
markers and at all intragenic polymorphisms detected
in the mutation screen were additionally screened for a
whole gene deletion, through use of a method of mul-
tiplex PCR amplification of short fluorescent fragments,
using MLH1 as a control (Charbonnier et al. 2002). 6-
Fam–labeled primers for NSD1 exons 6, 8, and 21 and
MLH1 exons 18 and 4 were simultaneously PCR am-
plified. The resulting product was electrophoresed on an
ABI 3100 sequencer (ABI Perkin Elmer) and analyzed
with GENOTYPER software. All experiments were re-
peated six times. A consistent, reproducible 0.5 reduc-
tion (i.e., a reduction by one half) in peak height of all
three NSD1 exons, compared with MLH1 exons, was
taken as indicative of a deletion of one copy of NSD1
in that individual.
NSD1 Mutation Analyses
NSD1 contains 23 exons, the first of which is noncod-
ing. Primers were designed to amplify the remaining 22
exons and intron-exon boundaries of NSD1, using con-
formation-sensitive gel electrophoresis (CSGE) (Ganguly
et al. 1993). In our laboratory, we estimate the sensitivity
of CSGE to detect small deletions/insertions and point
mutations to be 90%. Primer sequences were designed
using the NSD1 genomic sequence (GenBank accession
number AF395588) and Primer 3 software. Exons 1400
bp were amplified using overlapping primer pairs. The
gene was screened in 40 fragments. The primer sequences
and sizes for the NSD1 mutation screen are shown in
table 3. All fragments were amplified using a touchdown
68C–50C protocol. Genomic DNA from patients show-
ing mobility shifts on CSGE was bidirectionally sequenced
using the BigDyeTerminator Cycle Sequencing Kit and a
Douglas et al.: NSD1 Mutations in Sotos and Weaver Syndromes 135
Table 1
Phenotypic Delineation of Patients with Childhood Overgrowth, Indicating Numbers of Affected Individuals and Parents Analyzed and the
Number of Patients with NSD1 Deletions and Mutations
GROUP PHENOTYPE
NO. OF
PATIENTS
ANALYZED
NO. OF PATIENTS WITH
NSD1
Deletions
NSD1
Mutations
Both Parents
Analyzed
One Parent
Analyzed
1 Classic Sotos syndrome 37 2 26 19 6
2 Sotos-like, but with atypical features 13 1 3 6 0
3 Weaver syndrome 7 0 3 5 2
4 Childhood overgrowth, but not Sotos or Weaver syndrome 18 0 0 4 11
3100 automated sequencer (ABI Perkin Elmer). All 75
patients were screened through all 40 fragments. In mu-
tation-positive patients, parental DNA (if available) was
analyzed by direct sequencing for the specific mutation
identified in the proband. Mutations were considered
pathogenic if they were likely to result in premature trun-
cation of the protein or in exon skipping (small insertions
and deletions, nonsense and splice-site mutations). To de-
cide whether missense alterations were likely to be path-
ogenic, we considered whether they occurred de novo,
whether they were present in 200 control individuals, and
whether they were at conserved residues in the mouse
orthologue and human paralogues. For comparison of
NSD1 missense mutations with mouse nsd1 and human
NSD2 and NSD3, the BLAST program was used (NCBI
BLAST Home Page).
Results
NSD1 Microdeletion Analyses
We analyzed DNA from 75 patients and 87 parents
at nine microsatellite markers in the 1.5-Mb interval
encompassing NSD1, including two intragenic markers
(SOT3 and SOT17). In 69 patients, a microdeletion en-
compassing NSD1 was excluded by the presence of two
alleles of differing sizes at one or both intragenic markers
and/or by heterozygosity for NSD1 mutations or poly-
morphisms detected by CSGE. Three patients (COG25,
COG44, and COG70) are highly likely to have hemi-
zygous deletions resulting in the loss of one whole copy
of NSD1 (and surrounding genes), since they carry a
single allele at a minimum of eight of the nine markers
analyzed (fig. 2A). For COG25, DNA from both parents
was available and confirmed a maternal deletion telo-
meric to SOT12 in the affected child (fig. 2A). In ad-
dition, the multiplex PCR demonstrated a consistent 0.5
reduction in peak height of NSD1 exons (fig. 2B).
COG70 has a single allele at all nine SOT markers and
is homozygous for all 15 intragenic polymorphisms.
Moreover, the multiplex PCR demonstrated a 0.5 re-
duction in NSD1 exon peak height in six separate ex-
periments. Thus, although we do not have parental DNA
or cells for FISH analysis, our results very strongly sug-
gest that COG70 has a deletion of one copy of NSD1.
Similarly, COG44 has a single allele at eight consecutive
markers, is homozygous for all intragenic polymor-
phisms, and consistently shows a 0.5 reduction in peak
height of NSD1 exons in the multiplex PCR (fig. 2).
Only maternal DNA was available and was consistent
with transmission of a maternal allele at all SOT markers
(fig. 2A). Thus, it is very likely that COG44 has a de-
letion of the paternal copy of NSD1. Three patients
(COG7, COG23, and COG50) were homozygous at the
two intragenic markers and were homozygous for the
common alleles at the 15 NSD1 polymorphisms, but
they did not show reduction of NSD1 exon peak height
in the multiplex PCR and are thus very unlikely to have
a whole gene deletion.
NSD1 Mutation Analyses
Genomic DNA from all 75 patients was screened for
intragenic NSD1 mutations by CSGE. In total, 32 mu-
tations were identified (table 4). Twenty-one mutations
were predicted to result in premature truncation of the
protein because of frameshift or nonsense alterations.
Two splice-site mutations were identified and are also
likely to be pathogenic, although the precise effect of
these mutations was not determined. The truncating mu-
tations were spread fairly evenly through the gene, be-
tween exons 4 and 23 (fig. 3). One mutation (R604X)
was identified in two separate patients, COG22 and
COG54. Analysis of parental samples for COG22 dem-
onstrated that the mutation had occurred de novo and,
hence, these two identical mutations have arisen sepa-
rately. The mutation is at a CpG dinucleotide, which is
known to be particularly susceptible to mutation (Coo-
per and Krawczak 1989). All other mutations were iden-
tified only once. Samples from both parents were avail-
able for eight patients with truncating NSD1 mutations,
and all were wild type, indicating the mutations had
occurred de novo in the affected child.
We identified nine missense mutations, and these were
clustered in the C-terminal half ofNSD1, between exons
13 and 23 (fig. 3). For seven patients with missense mu-
tations, analysis of parental samples indicated the mu-
tations had occurred de novo and, hence, are highly
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Table 2
Primer Sequences for Chromosome 5q35 Microsatellite Markers and Positions Relative to NSD1
MARKER
POSITION
RELATIVE
TO NSD1a
(kb)
PRIMER SEQUENCE
(5′r3′)
SIZE
(bp)Forward Reverse
SOT12 645 cen GATAAACCACAACCCCAACC ACGTAGCTAGGCACCACCAT 172
SOT11 391 cen CAGGCTCGTTCATTCACAAA AGGCAAAATTTCCTCCCATC 203
SOT10 383 cen GACTGCAAGGAGCTTGAACC GGGCCACCATACACTTGTTC 148
SOT1 181 cen GGGAAAGTTGACAGGATTTTGA GCAAATAGGGCATCTGCAAG 226
SOT4 26 cen GGTCCTCCACACATTCTGCT ACATGCCCTATGACCTGGAA 201
SOT3 Intragenic GCACCGTTTTACAGTCCTACTT CTGCAGTGAGCCAAGACCAT 216
SOT17 Intragenic GGCATTGTTCCTGGATGAGA GGAGATGGATGTTGCAGTGA 201
SOT19 284 tel CCCCTTTGTATGGGGTCTTT CCTGGGTGACACAGTGAGACT 201
SOT20 290 tel CCAGTTCCATCCAAGACACA CATTTGATCCAGAAATCCCACT 267
a The position relative to the first base of NSD1 is given for markers centromeric (cen) to NSD1. The
position relative to the last base of NSD1 is given for markers telomeric (tel) to NSD1. Marker positions are
based on the UCSC Human Genome Project Working Draft.
likely to be pathogenic (table 4). Samples from both
parents were not available for the remaining missense
alterations; however, these mutations (C1925R and
C1674W) were not present in the other 74 patients or
200 control individuals. Further evidence supporting a
pathogenic role for the missense alterations was ob-
tained from analysis of their position within NSD1. All
occur at residues within functional domains and are con-
served not only in mouse Nsd1 but also in the two
known human paralogues of NSD1, NSD2 (also known
as MMSET [Chesi et al. 1998] and WHSC1 [Stec et al.
1998]) and NSD3 (Angrand et al. 2001). Four missense
mutations (H1616L, L1637P, C1674W, and H2143E)
occur within the PHD domains, and three of these occur
at consensus Cys/His residues and would be expected to
have critical effects on substrate binding by these do-
mains (fig. 4A). Two further missense mutations also
occur at Cys residues: C2183S, in a Cys/His-rich region
adjacent to PHD-V, which may correspond to another
zinc finger–like motif and is present in mouse Nsd1 and
in human NSD2 and NSD3 (fig. 4B); and C1925R,
which is in the consensus motif of the SAC domain (fig.
4B). The R2005Q and R2017Q mutations occur within
the highly conserved SET domain (fig. 4B), and G1792V
is in the PWWP-II domain (fig. 4B).
We identified 15 polymorphisms (table 5). These were
considered nonpathogenic, since they were identified in
multiple individuals, both affected and unaffected, and
were present in patients with a separate pathogenic
NSD1 mutation. Moreover, several are intronic or result
in synonymous amino acid changes.
Correlation of NSD1 Aberrations and Phenotype
There was a strong correlation between the presence
of NSD1 mutation and phenotype (table 1; fig. 3).
Twenty-six of 32 mutations and two of three deletions
were identified in group 1 (classic Sotos) patients. Thus,
we identified a pathogenic NSD1 aberration in 28 of 37
group 1 patients, a frequency of 76%. Of 13 group 2
(Sotos-like) patients, 3 harbored NSD1 mutations, and
1 group 2 patient had an NSD1 deletion. The overall
frequency of NSD1 alterations in the group 2 patients
was thus 4 of 13 patients (30%). In contrast, none of
the 18 group 4 (non-Sotos, non-Weaver overgrowth) pa-
tients harbored either NSD1 mutations or deletions. Of
7 patients with Weaver syndrome, 3 (42%) harbored
NSD1 mutations (fig. 3). Intriguingly, these were all
within a 40–amino acid region between 2142 and 2184
in exons 22 and 23 and were the most C-terminal mu-
tations identified (fig. 3).
Discussion
Recently, deletions and mutations in NSD1 were re-
ported in a series of Japanese patients with Sotos syn-
drome (Kurotaki et al. 2002). To evaluate the contri-
bution of NSD1 aberrations to childhood overgrowth
syndromes, we have undertaken an analysis of NSD1 in
a phenotypically characterized series of childhood over-
growth syndrome cases from Britain. Our results dem-
onstrate that 76% of patients with Sotos syndrome har-
bor deleterious alterations of NSD1. Thus, functional
abrogation of one copy of NSD1 is the major—and pos-
sibly the only—cause of Sotos syndrome. We did not
identify mutations or deletions in nine patients with clas-
sic Sotos syndrome. Although it is possible that muta-
tions of another gene can lead to Sotos syndrome in a
minority of cases, it is equally plausible that the patients
with unexplained Sotos syndrome in our series have un-
derlying aberrations in NSD1 that were not detected,
either because of lack of sensitivity of the screening tech-
nique or because they result in alterations that are not
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Table 3
Primer Pairs Used to Amplify the NSD1 Coding Sequence, and Sizes of PCR Products
EXON
PRIMER SEQUENCE
(5′r3′)
SIZE
(bp)Forward Reverse
2A AGAGTCGAGTCAGATGGCCTA GATCCATCAGCAGACCCATT 355
2B GTGGAACATCCCAAAATGCT TCTGTGACTGGCTGTTCTGG 367
2C TGGCTTTCTGCACTTTGAGA GAAGGGCTGCTTTTTCATTG 317
2D GCCATTCTTGCCATTAGCTC TTTCCCTTTAAGTGGCCTGT 323
3 TGCTTTTTCAGAAGGCTAATAGG TCATTCACAAAATGTTCCAAGG 332
4 GCAATGATGTGGCTGTTCTC TCCAATCTGGGAAACAGAGC 364
5A TCTGATTTCATCTCCCTTTTCC GGCTTTTCCTTCTCATCTGC 315
5B ATGCCATTTGAAGACTGCAC TCCACAGGAAGAAAACAGAAAA 360
5C TCCACAGGAAGAAAACAGAAAA TATGGGATCCAGGTCACTGC 323
5D GGAAAAGCGAAGTGATTCCA TCTGACTGGGGTTTGTGAAC 348
5E GGGTTGTACTAAGAGTGCAGAGC TTAGAAATGCTGGCCAAAGG 348
5F TATGGCAGAACCCCCAGTTA CGCTGCTCCTTCGTCTTACT 381
5G TGGAACATCAAAGCCATCAA CGCCAGATAATGCAGAGTCA 332
5H GGCTCCACACACAATTCAGA CTCCCTGCAGTACAGCATCA 334
5I ATGCTTTTTCAGCCCAAATG CTGGGCCTTTTCCGTTTT 312
5J GATGTGCATTTCGATAGCAAG GCTCTGTCAGTGGTTCCTCA 343
5K GGTCTTACTTCCTAGTGACC TATCACATTTAGATGTCCTTAC 255
6 ATGTGGTTTCCCATCTGGTT TGACATTGAAGATAAAATTGCAG 300
7 AACAATTTTGGCCTGTGGAC TCAAATACTGAGACCCCAACC 345
8 TTGTGCCCAGTTTCTAAATCA TGCAAAACAGCCTTTCATGT 327
9 TGGCAGCTGACAATTCAGAC CTCACTGGTCGGGCTTACAC 268
10 CCCGTTTTCCTAATCCACAA CCTCTGGCGTGAAAAGTAGC 310
11 AGGGGGTCAAATGGAAGAGA GATGGAGTGGGTTTCCCTTT 273
12 TCACCTCCTTTTCTGCCACT CCCAGTGTTGCCACAAAATA 337
13 TGGGTTCAGACGATGTCAAA TCTGTTGCCAATTAAACTGAGG 383
14 TCCATCATCTTAGTGGTCATTCC TCCAGTGGCAATATGATGAAA 411
15 TGGATGTACACATACATGACTTGC AAGAGGGGAGGAGTACCATGA 342
16 ATTTTCCTAATGCCTTGCAG GGCAGTTTCAAAATGGAGCA 364
17 TCTCCAACTTAAAGGGGAAAAA AGAGTGGGAAGAGCCAGCTA 273
18 GGACGTGAATTGTCTTCTGCT TCAAGCAACTGCAAAGAGGA 381
19 CTGCTGCTGACAGTGGTAGG TATGGCTGGGACAACACAAA 386
20 AAATTTTAATCCACAGCAGAGGTC GTGGTGATGGTTGCACAAAA 356
21 TCTTGGGAGTTGGTATCCTTTG AACACTGTTAGGGAGGGAGGA 257
22 GAATGAGGCTCAGAGAGGGTA AAATGGCATGAGACCCTGAG 360
23A GGAAGGTCATCATCCACACC GATTGCTCTGCCAGGTGAGT 356
23B TGGGGAGATCCGTGAGTATG CTGGTCACTGGAGAGGGTTT 369
23C AATCCCAATCCTTGGTTTCC GGTCTGGACCACAGCTGATA 380
23D CCTACTGACAAACCCCATGC CTGCTGCTTTCCCAGATGTC 346
23E AGCAAAGGTCTGGGGCATA CAGGGACTTTGCTCTGTGGT 395
23F TTTTAGGTCTCTCGGGAAGG GGGGCAGCTTGTTTGTTC 331
detectable by our methods, such as genomic rearrange-
ments of NSD1 or regulatory mutations.
The frequency (76%) of pathogenicNSD1 aberrations
in our series of patients with Sotos syndrome is very
similar to the 77% reported by Kurotaki et al. (2002).
However, the spectrum of NSD1 aberrations is rather
different in the two series. In our series, whole gene de-
letions occurred in only 8% (3/37) of patients with Sotos
syndrome, compared with 66% (20/30) of patients in the
Japanese study. Furthermore, Kurotaki et al. (2002) re-
ported a common 2.2-Mb deletion in 19 patients. Al-
though we have not defined the precise breakpoints in
our three patients with Sotos syndrome who have dele-
tions, the centromeric breakpoint in COG25 must be
telomeric to SOT12, and the telomeric breakpoint in
COG44 must be centromeric to SOT21. This positions
these breakpoints well within the 2.2-Mb interval re-
ported, and, thus, these two patients are very unlikely to
carry the common deletion found in the Japanese patients
with Sotos syndrome. Conversely, we detected intragen-
ic mutations in 70% (26/37) of our patients with Sotos
syndrome, whereas the Japanese group identified NSD1
mutations in only 10% (4/38). Clinical evaluation of our
three patients with 5q35 microdeletions suggest they have
more-severe learning difficulties, a coarser facial gestalt,
and less pronounced overgrowth than is typical for pa-
tients with intragenic NSD1 mutations.
The reasons for the disparity in NSD1 pathogenetic
Figure 2 NSD1 deletions in three patients with childhood overgrowth—COG25, COG44, and COG70. A, Marker allele haplotypes for
nine microsatellite markers spanning NSD1, demonstrating maternal deletion in COG25, probable paternal deletion in COG44, and deletion
of unknown origin in COG70. B, Fluorescent multiplex PCR demonstrating a 0.5 reduction of NSD1 exons relative to MLH1, in COG25,
COG44, and COG70, and a normal ratio in two control samples: (1) the mother of COG25 and (2) COG33 (who has an intragenic NSD1
mutation). The Y-axis shows fluorescence (in arbitrary units), and the X-axis indicates the size (in bp).
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Table 4
Pathogenic NSD1 Mutations Identified in 75 Patients with Childhood Overgrowth
Mutation
Protein
Changea Exon Patient
Phenotypic
Group
Results of Mutation
Analysis of
Parental Samplesb
Deletion:
1171delC Q391fsX418 4 COG14 1 No mutation in parents
1727delA N576fsX598 5 COG57 1 …
2576delAT H859fsX873 5 COG69 2 …
3383delCT S1128fsX1129 5 COG67 1 …
4883delT M1628fsX1641 13 COG45 1 No mutation in mother
6001delC L2001fsX2001 19 COG77 1 …
6302delA K2101fsX2149 22 COG29 1 No mutation in parents
Insertion:
2807-8insA Y936fsX936 5 COG75 1 …
3549-50insT E1184fsX1184 5 COG73 2 …
5008-9insG A1670fsX1672 14 COG66 1 …
5744-5insT M1915fsX1919 18 COG30 1 No mutation in parents
6431-2ins17 A2144fsX2155 22 COG17 1 No mutation in parents
6450-1insC K2151fsX2165 22 COG6 3 No mutation in mother
Nonsense:
1492CrT R498X 5 COG51 2 …
1810CrT R604X 5 COG22 1 No mutation in parents
1810CrT R604X 5 COG54 1 …
2323CrT Q775X 5 COG74 1 No mutation in parents
4411CrT R1471X 10 COG33 1 No mutation in mother
4417CrT R1473X 10 COG21 1 No mutation in parents
5332CrT R1778X 16 COG63 1 …
5861GrA W1954X 18 COG28 1 No mutation in parents
Splice-site:
IVS15-1GrC Int15 COG72 1 …
IVS16-2delA Int16 COG35 1 No mutation in mother
Missense:
4847ArT H1616L 13 COG24 1 No mutation in parents
4910TrC L1637P 13 COG31 1 No mutation in parents
5022CrG C1674W 14 COG52 1 …
5375GrT G1792V 16 COG76 1 No mutation in parents
5773TrC C1925R 18 COG34 1 No mutation in mother
6014GrA R2005Q 20 COG5 1 No mutation in parents
6050GrA R2017Q 20 COG27 1 No mutation in parents
6429CrG H2143E 22 COG15 3 No mutation in parents
6548GrC C2183S 23 COG62 3 No mutation in parents
a Frameshift mutations are designated according to the following example: Q391fsX418 refers
to a frameshift mutation in which Q391 is the first amino acid altered, with termination of the
ORF at residue 418.
b If the result of a parental analysis is not given, the sample was not available for analysis.
spectra in the Japanese and British populations are not
clear. It could simply reflect the particular patients an-
alyzed in these initial studies, and, as more cases are
screened, the frequencies of mutations and deletions in
the different populations may become more compara-
ble. Indeed, it is quite likely that the difference in NSD1
mutation frequency is explicable by a relative enrich-
ment of true Sotos syndrome in our group 1, since many
of the 75 patients we analyzed were initially referred
with a potential diagnosis of Sotos syndrome (i.e., group
1) but were rescored as group 2, 3, or 4 by clinical
geneticists with expertise in overgrowth conditions.
The disparity in the incidence of NSD1 deletions in
the two series is more difficult to resolve. We cannot be
missing many deletions, since 69 of 75 patients had
NSD1 mutations and/or polymorphisms that were iden-
tified by a heteroduplex assay (CSGE) and, hence, were
only detectable if two copies of the gene were present.
A possible explanation is a specific Japanese overgrowth
phenotype, caused by a 5q35 microdeletion, which is
very uncommon in Britain. A separate “Japanese Sotos”
phenotype has been postulated in the past, to account
for the higher incidence of congenital heart disease in
Japanese patients with Sotos syndrome (Kaneko et al.
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Figure 3 Schematic representation of NSD1, showing the distribution of intragenic mutations identified in the present study and the
associated phenotype. Exons of NSD1 are shown as boxes with the exon number underneath. Functional domains of NSD1 are shown as
shaded boxes, with the domain name above. Mutations are shown as triangles, with truncating mutations (insertions, deletions, nonsense, and
splice-site) above the gene and missense mutations below the gene. One mutation (R604X) was identified twice and is depicted as two triangles,
one above the other.
1987). However, the Japanese NSD1 deletions occurred
in patients with sporadic Sotos syndrome and, thus,
seem unlikely to be caused by a single Japanese founder.
Whatever the reason(s) for these apparent differences,
the very high frequency of mutations in our study clearly
indicates that intragenic NSD1 mutations are the major
cause of Sotos syndrome in the British population. We
therefore believe that Sotos syndrome should be con-
sidered a single-gene disorder analogous to neurofibro-
matosis type 1, in which the majority of cases are due
to NF1 mutations, with a minor proportion (5%–10%)
attributable to chromosomal aberrations that result in
deletion of one copy of the gene (Lopez-Correa et al.
2000). We do not consider Sotos syndrome a genomic
disorder, comparable to syndromes such as Williams or
Smith-Magenis, in which the predominant pathogenetic
mechanism is a recurrent chromosomal microdeletion
(Stankiewicz and Lupski 2002).
Given that Sotos syndrome is generally caused by
hemizygous mutations in an autosomal nonimprinted
gene, it is of interest that it does not behave as an au-
tosomal dominant trait and that familial cases are so
rare. The mental impairment in Sotos syndrome is usu-
ally in the mild/moderate range and is not sufficiently
severe to account for the extreme paucity of familial
Sotos cases. All of the 15 mutations in which we could
assess inheritance occurred de novo, and the 5q35 mi-
crosatellite analyses confirmed paternity in all cases.
Furthermore, of the 37 group 1 patients with classic
Sotos syndrome, only one, COG76, has a family history
of the disease, in that her daughter also has Sotos syn-
drome. Unfortunately, DNA from the daughter was not
available for analysis, but she is very likely to carry the
G1762V mutation that has occurred de novo in her
mother.
The most likely reason for the lack of familial cases
is an underlying defect in fertility associated withNSD1
mutations. Delayed menarche, oligomenorrhea, and in-
creases in the rate of spontaneous abortions and still-
births have been reported in patients with Sotos syn-
drome (Opitz et al. 1998). Since the diagnostic criteria
for the syndrome were reported only relatively recently,
it is only now that a generation of children with diag-
nosed Sotos syndrome are reaching reproductive age,
and, thus, the incidence and nature of fertility defects
may become clearer in the near future. It is possible that
rare cases of familial Sotos syndrome may be explicable
by NSD1 mutations that result in Sotos syndrome but
not in reproductive impairment. It is noteworthy, in this
regard, that the only patient in our series who has a
family history of Sotos syndrome has a missense mu-
tation in the PWWP-II domain, and functions of other
NSD1 domains may be intact in carriers of this mu-
tation. However, further investigation of patients with
familial Sotos syndrome and of the functions of NSD1
are required before conclusions about the postulated
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Figure 4 NSD1 missense mutations in patients with childhood overgrowth. Residues altered by missense mutations are shown in red
boxes. Consensus residues in the PHD and SAC domains are shown in black boxes. Conserved residues in NSD1, mouse Nsd1, NSD2, and
NSD3 are shown in shaded boxes. A, The alignment of five PHD domains in NSD1 and the position of the missense mutations identified in
the present study. B, Missense mutations in PWWPII, SAC, SET, and C/H-rich domains and in corresponding regions in mouse Nsd1, NSD2,
and NSD3.
reproductive impairment in Sotos syndrome can be
drawn.
We analyzed seven patients with Weaver syndrome
and identified threeNSD1mutations. Weaver syndrome
is a childhood overgrowth syndrome that shares many
phenotypic features with Sotos syndrome but is much
less common. Identification of NSD1 mutations in pa-
tients with Weaver syndrome demonstrates that the two
conditions are allelic. However, we have investigated
only a small number of patients with Weaver syndrome,
and NSD1 mutations were not identified in over half
of them, all of whom have phenotypes typical of the
syndrome. It remains possible, therefore, that a sepa-
rate, second Weaver syndrome gene exists. Additional
patients with Weaver syndrome need to be screened, to
more accurately assess the frequency of NSD1 muta-
tions in this condition.
Our results revealed a strong correlation between
clinical phenotype and presence of a deleterious NSD1
mutation or deletion. Most striking was the absence of
any mutations or deletions in the 18 group 4 patients
with a childhood overgrowth syndrome that was defi-
nitely not either Sotos syndrome or Weaver syndrome.
The group 4 patients are likely to have a heterogeneous
group of conditions, and the majority of patients in this
group were felt to have an overgrowth condition that
did not correspond to any recognized syndrome. Four
of 13 group 2 (Sotos-like, but with some atypical fea-
tures) patients harbored pathogenic NSD1 alterations.
The individual phenotypic scores for three of these were
available, and, for each, one clinician (who had actually
met the patient) scored the patient as group 1, whereas
the other two (who only reviewed photographs) scored
the patient as group 2. The fourth mutation-positive
group 2 patient was part of the original study that es-
tablished the diagnostic criteria of Sotos syndrome (Cole
and Hughes 1994). This patient was initially scored as
group 1 on the basis of the facial gestalt alone but was
rescored as group 2 because his bone age was not ad-
vanced. Thus, our results suggest thatNSD1 aberrations
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Table 5
Polymorphisms in the NSD1
Gene
Location and
Nucleotide Change
Protein
Change
Exon 5:
1749GrA E583E
1792TrC L599L
1840TrG V614L
2071GrA A691T
2176TrC S726P
3106GrC A1036P
3271CrA L1091I
3705TrC N1235N
Intron 10:
IVS10-9delT …
Intron 17:
IVS17-22GrA …
Intron 18:
1VS18-132GrA …
Exon 23:
6750GrA M2250I
6782TrC M2261T
6829CrT L2277L
6903GrC G2301G
are rather specific for Sotos and Weaver syndromes, and
the frequency in other phenotypes is likely to be very
low. However, given the challenges of accurate clinical
diagnosis of Sotos and Weaver syndromes, a low thresh-
old for diagnostic NSD1 screening in overgrowth con-
ditions would be prudent, until the associated range of
phenotypes becomes clearer.
Our data provide preliminary indications of possi-
ble genotype-phenotype associations. The majority of
known NSD1 functional domains are in exons 11–23,
and all missense mutations we identified were clustered
in these domains, within highly conserved regions in
mouse Nsd1 and human NSD2 and NSD3. It is possible
that missense mutations outside these domains do not
cause Sotos syndrome. Perhaps the most intriguing find-
ing is the clustering of the three Weaver syndrome mu-
tations within a 40–amino acid region in exons 22 and
23. This region is in the PHD-V domain and the ad-
jacent Cys/His-rich region, and all are 5′ to the SET
domain, which may retain some function. It is possible
that the position of mutations in the patients with Wea-
ver syndrome is not coincidental and reflects a genotype-
phenotype correlation, whereby mutations within the
C-terminal region of the gene, after the SET domain,
give rise to a Weaver phenotype. However, a mutation
within this 40–amino acid region was also identified in
a patient with classic Sotos syndrome, indicating that
the correlation, if substantiated, cannot be completely
specific.
Both Sotos and Weaver syndromes are associated
with a wide spectrum of additional abnormalities, in-
cluding congenital heart disease, scoliosis, and cancer.
Investigation of mutational spectra in relation to the
phenotype of individual patients may reveal further ge-
notype-phenotype associations and may also be helpful
in clarifying the complex functions and interactions of
NSD1. The reason why functional abrogation ofNSD1,
a bifunctional transcriptional regulator with a postu-
lated role in histone and chromatin modification, results
in overgrowth and the wide phenotypic spectrum of
Sotos and Weaver syndromes remains to be elucidated.
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